Cancer Patients Need More Info on Side Effects of Radiation Tx
WEDNESDAY, Nov. 27, 2019 -- Although most cancer patients do not experience anticipated potential adverse effects of radiation therapy, more than one-third have adverse effects that they wish
Sex Isnt Always What Drives Sexting
FRIDAY, Nov. 29, 2019 -- "Sexting" may sound salacious, but it isnt always about sex, a new study shows.
In fact, two-thirds of adults who send these sexually oriented text messages dont have sex in mind at all, the
Leg Pain Could Spell Peripheral Artery Disease for Some
FRIDAY, Nov. 29, 2019 -- Leg pain while walking or doing other activities could be a sign of peripheral artery disease, an expert says.
Peripheral artery disease (PAD) develops silently, narrow
FRIDAY, Nov. 22, 2019 -- Restrictive Medicaid policies are associated with a reduced proportion of payment by Medicaid for liver transplantation (LT) for alcohol-related liver disease (ALD) since 2011, according to a study published online Nov. 8 in Hepat
FDA Approves Givlaari
FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2019 --Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S
FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
21 November 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia